-
1
-
2
Lab-Scale Methodology for New-Make Bourbon Whiskey Production
Published 2023-01-01Get full text
Article -
3
-
4
-
5
-
6
Identification of elongation factor‐2 as a novel regulator of mitochondrial fission
Published 2022-07-01Get full text
Article -
7
The policy landscape for naloxone distribution in four states highly impacted by fatal opioid overdoses
Published 2023-03-01Get full text
Article -
8
1115 RAIL biomarkers capture response to induction therapy in pediatric patients during induction therapy
Published 2022-12-01Article -
9
-
10
-
11
-
12
The Phase 3 INVIGORATE Trial of Reproxalap in Patients with Seasonal Allergic Conjunctivitis
Published 2023-12-01“…Christopher E Starr,1 Kelly K Nichols,2 Jacob R Lang,3 Todd C Brady4 1Department of Ophthalmology, Weill Cornell Medicine, New York, NY, USA; 2School of Optometry, University of Alabama, Birmingham, AL, USA; 3College of Optometry, the Ohio State University, Columbus, OH, USA; 4Aldeyra Therapeutics, Lexington, MA, USACorrespondence: Todd C Brady, Aldeyra Therapeutics, 131 Hartwell Avenue, Suite 320, Lexington, MA, 02421, USA, Email tbrady@aldeyra.comPurpose: There is an unmet need for new treatments for allergic conjunctivitis.Objective: To assess the activity of reproxalap, a novel reactive aldehyde species modulator, in a real-world model of seasonal allergen exposure.Methods: The INVIGORATE Trial, a prospective, quadruple-masked, vehicle-controlled, crossover, sequence-randomized Phase 3 trial, tested the efficacy of reproxalap in adults with a history of moderate to severe allergic conjunctivitis, ragweed pollen allergy, and allergen chamber-induced ocular itching and redness. …”
Get full text
Article -
13
Results on elastic cross sections in proton–proton collisions at s=510 GeV with the STAR detector at RHIC
Published 2024-05-01Get full text
Article -
14
-
15
-
16
Elliptic flow of heavy-flavor decay electrons in Au+Au collisions at sNN = 27 and 54.4 GeV at RHIC
Published 2023-09-01Get full text
Article -
17
Energy dependence of intermittency for charged hadrons in Au+Au collisions at RHIC
Published 2023-10-01Get full text
Article -
18
CT based bone mineral density as a predictor of proximal junctional fractures
Published 2022-09-01Get full text
Article -
19
Psychometric Analysis of the Patient-Reported Hypoparathyroidism Symptom Diary Symptom Subscale Using Data from Two Clinical Trials
Published 2023-11-01“…Lauren Nelson,1 Steven W Ing,2 Mishaela R Rubin,3 Jia Ma,1 Susan Martin,4 Rohini Sen,5 Olulade Ayodele6 1RTI Health Solutions, Research Triangle Park, NC, USA; 2Department of Endocrinology, Diabetes and Metabolism, Ohio State University Wexner Medical Center, Columbus, OH, USA; 3Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA; 4RTI Health Solutions, Ann Arbor, MI, USA; 5Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA, USA; 6Takeda Development Center Americas Inc., Lexington, MA, USACorrespondence: Lauren Nelson, RTI Health Solutions, 3040 East Cornwalls Road, PO Box 12194, Research Triangle Park, NC, 27709-2194, USA, Tel +1 919-541-6000 ext. 1541, Email lnelson@rti.orgPurpose: The hypoparathyroidism symptom diary (HypoPT-SD) is a disease-specific patient-reported outcome (PRO) tool comprising a 7-item symptom subscale, a 4-item impact subscale and 1-item anxiety, and sadness or depression components. …”
Get full text
Article -
20
KL2 scholars’ perceptions of factors contributing to sustained translational science career success
Published 2022-01-01Get full text
Article